|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7888121B2
(en)
*
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
WO2011049627A1
(en)
|
2009-10-22 |
2011-04-28 |
Dow Agrosciences Llc |
Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
|
|
US12492376B2
(en)
|
2009-10-29 |
2025-12-09 |
The Trustees Of Dartmouth College |
T-cell receptor-deficient T cell compositions
|
|
US9273283B2
(en)
*
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
US9181527B2
(en)
|
2009-10-29 |
2015-11-10 |
The Trustees Of Dartmouth College |
T cell receptor-deficient T cell compositions
|
|
WO2012145384A1
(en)
|
2011-04-20 |
2012-10-26 |
University Of Washington Through Its Center For Commercialization |
Beta-2 microglobulin-deficient cells
|
|
AU2012286901B2
(en)
|
2011-07-25 |
2016-10-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US9637739B2
(en)
*
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
PT2838548T
(pt)
*
|
2012-04-17 |
2023-10-13 |
Univ Washington Through Its Center For Commercialization |
Células deficientes em hla de classe ii, células deficientes em hla de classe i capazes de expressar proteínas de hla de classe ii, e utilizações das mesmas
|
|
KR101904508B1
(ko)
*
|
2012-04-25 |
2018-10-04 |
리제너론 파마슈티칼스 인코포레이티드 |
큰 표적화 벡터를 사용한 뉴클레아제-중재된 표적화
|
|
EP3505537A1
(en)
|
2012-05-07 |
2019-07-03 |
Trustees of Dartmouth College |
Anti-b7-h6 antibody, fusion proteins, and methods of using the same
|
|
EP2855666B1
(en)
|
2012-05-25 |
2019-12-04 |
Cellectis |
Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
|
|
US20150017136A1
(en)
*
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
CA2886684C
(en)
|
2012-10-10 |
2023-09-19 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
|
US20140115728A1
(en)
|
2012-10-24 |
2014-04-24 |
A. Joseph Tector |
Double knockout (gt/cmah-ko) pigs, organs and tissues
|
|
US9970024B2
(en)
*
|
2012-12-17 |
2018-05-15 |
President And Fellows Of Harvard College |
RNA-guided human genome engineering
|
|
US20150037304A1
(en)
*
|
2013-03-12 |
2015-02-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of hla
|
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
US9499855B2
(en)
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
EP2975942B1
(en)
|
2013-03-21 |
2018-08-08 |
Sangamo Therapeutics, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
|
WO2014165707A2
(en)
*
|
2013-04-03 |
2014-10-09 |
Memorial Sloan-Kettering Cancer Center |
Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
|
|
KR20200136508A
(ko)
|
2013-04-16 |
2020-12-07 |
리제너론 파마슈티칼스 인코포레이티드 |
랫트 게놈의 표적화된 변형
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
US9629877B2
(en)
|
2013-05-14 |
2017-04-25 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (CAR) T-cells
|
|
SG11201509609SA
(en)
|
2013-05-24 |
2015-12-30 |
Univ Texas |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
WO2015057976A1
(en)
|
2013-10-17 |
2015-04-23 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
JP6174811B2
(ja)
|
2013-12-11 |
2017-08-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ゲノムの標的改変のための方法及び組成物
|
|
RU2714902C2
(ru)
|
2013-12-19 |
2020-02-20 |
Новартис Аг |
Химерные рецепторы антигена против мезотелина человека и их применение
|
|
EP3092049A1
(en)
|
2014-01-08 |
2016-11-16 |
Flodesign Sonics Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
|
KR102157924B1
(ko)
|
2014-02-14 |
2020-10-26 |
셀렉티스 |
면역 세포들 및 병리 세포들 둘 다에 존재하는 항원을 타겟팅하기 위하여 조작된 면역치료용 세포들
|
|
RU2021123419A
(ru)
|
2014-02-14 |
2021-10-22 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Химерные антигенные рецепторы и способы их получения
|
|
RU2752933C2
(ru)
|
2014-03-11 |
2021-08-11 |
Селлектис |
Способ создания т-клеток, пригодных для аллогенной трансплантации
|
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
|
MX370272B
(es)
|
2014-03-19 |
2019-12-09 |
Cellectis |
Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
|
|
ES2876263T3
(es)
|
2014-04-07 |
2021-11-12 |
Novartis Ag |
Tratamiento del cáncer usando receptor de antígeno quimérico anti-cd19
|
|
JP2017513472A
(ja)
|
2014-04-11 |
2017-06-01 |
セレクティスＣｅｌｌｅｃｔｉｓ |
アルギニンおよび／またはトリプトファン枯渇微小環境に対して抵抗性を有する免疫細胞を作製するための方法
|
|
CA2945620C
(en)
*
|
2014-04-14 |
2022-12-06 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
|
KR20200138445A
(ko)
*
|
2014-04-24 |
2020-12-09 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
|
|
RU2704283C9
(ru)
|
2014-06-06 |
2020-02-07 |
Регенерон Фармасьютикалз, Инк. |
Способы и композиции для модификации целевого локуса
|
|
PT3161128T
(pt)
|
2014-06-26 |
2018-11-21 |
Regeneron Pharma |
Métodos e composições para modificações genéticas alvejadas e métodos de utilização
|
|
GB201412494D0
(en)
*
|
2014-07-14 |
2014-08-27 |
Ospedale San Raffaele And Fond Telethon |
Vector production
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
SG11201700416TA
(en)
|
2014-07-21 |
2017-02-27 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
EP3174546B1
(en)
|
2014-07-31 |
2019-10-30 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
DK3183268T3
(da)
|
2014-08-19 |
2020-05-11 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
|
|
CN113699113A
(zh)
|
2014-09-16 |
2021-11-26 |
桑格摩治疗股份有限公司 |
用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
|
|
KR20210149228A
(ko)
|
2014-09-17 |
2021-12-08 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
MX2017006408A
(es)
*
|
2014-11-17 |
2018-03-23 |
Adicet Bio Inc |
Linfocitos t gamma delta modificados geneticamente.
|
|
EP3521437B1
(en)
|
2014-11-21 |
2025-01-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for targeted genetic modification using paired guide rnas
|
|
EP3025719B1
(en)
|
2014-11-26 |
2018-09-26 |
Miltenyi Biotec GmbH |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
SG11201704646YA
(en)
|
2014-12-19 |
2017-07-28 |
Regeneron Pharma |
Methods and compositions for targeted genetic modification through single-step multiple targeting
|
|
EP3245286A4
(en)
*
|
2015-01-17 |
2018-07-11 |
Zhejiang University |
Modified cells evoking reduced immunogenic responses
|
|
US20180002379A1
(en)
|
2015-01-21 |
2018-01-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
|
AU2016211671B2
(en)
|
2015-01-26 |
2022-05-26 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
MX382223B
(es)
|
2015-05-12 |
2025-03-13 |
Sangamo Therapeutics Inc |
Regulacion de expresion genica mediada por nucleasa.
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
US20180184630A1
(en)
*
|
2015-06-26 |
2018-07-05 |
Indiana University Research & Technology Corporation |
Transgenic pigs with genetic modifications of sla
|
|
CA2991301A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
AU2016307050A1
(en)
|
2015-08-11 |
2018-02-15 |
Cellectis |
Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
|
|
RS66924B1
(sr)
|
2015-09-23 |
2025-07-31 |
Sangamo Therapeutics Inc |
Htt represori i njihova upotreba
|
|
EP3940070A1
(en)
*
|
2015-10-05 |
2022-01-19 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
|
|
KR20250013291A
(ko)
|
2015-10-05 |
2025-01-31 |
프리시젼 바이오사이언시스 인코포레이티드 |
변형된 인간 t 세포 수용체 알파 불변 영역 유전자를 포함하는 유전자 변형된 세포
|
|
CN108290939B
(zh)
|
2015-10-16 |
2023-01-13 |
纽约市哥伦比亚大学理事会 |
用于抑制谱系特异性抗原的组合物和方法
|
|
AU2016343887B2
(en)
|
2015-10-28 |
2023-04-06 |
Sangamo Therapeutics, Inc. |
Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
|
|
PT3371314T
(pt)
|
2015-11-04 |
2023-08-31 |
Fate Therapeutics Inc |
Modificação genómica de células pluripotentes
|
|
CA3003152A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
AU2016361350B2
(en)
|
2015-11-23 |
2023-04-06 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
|
CN108699557B
(zh)
|
2015-12-04 |
2025-08-15 |
诺华股份有限公司 |
用于免疫肿瘤学的组合物和方法
|
|
AU2016374253B2
(en)
|
2015-12-18 |
2021-10-21 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the MHC cell receptor
|
|
EP3389677B1
(en)
|
2015-12-18 |
2024-06-26 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the t cell receptor
|
|
EP4219689A3
(en)
|
2015-12-30 |
2023-12-20 |
Novartis AG |
Immune effector cell therapies with enhanced efficacy
|
|
CA3010738A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
CA3011049A1
(en)
|
2016-02-02 |
2017-08-10 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
EP4628587A2
(en)
|
2016-04-15 |
2025-10-08 |
Memorial Sloan Kettering Cancer Center |
Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
|
|
SI3443096T1
(sl)
|
2016-04-15 |
2023-07-31 |
Novartis Ag |
Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
WO2017197347A1
(en)
|
2016-05-12 |
2017-11-16 |
Adicet Bio, Inc. |
METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
|
|
NZ747857A
(en)
|
2016-05-20 |
2023-01-27 |
Regeneron Pharma |
Methods for breaking immunological tolerance using multiple guide rnas
|
|
US20190336504A1
(en)
|
2016-07-15 |
2019-11-07 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
BR112019003327A2
(pt)
|
2016-08-24 |
2019-07-02 |
Sangamo Therapeutics, Inc. |
nucleases manipuladas de alvo específico
|
|
CA3034882A1
(en)
|
2016-08-24 |
2018-03-01 |
Sangamo Therapeutics, Inc. |
Regulation of gene expression using engineered nucleases
|
|
EP3509645A4
(en)
|
2016-09-07 |
2020-06-17 |
Sangamo Therapeutics, Inc. |
MODULATION OF LIVER GENES
|
|
EP3519577A1
(en)
|
2016-09-28 |
2019-08-07 |
Novartis AG |
Porous membrane-based macromolecule delivery system
|
|
EP3528852B1
(en)
|
2016-10-20 |
2025-09-03 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of fabry disease
|
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
|
AU2017347928A1
(en)
|
2016-10-31 |
2019-05-09 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
EP3535396A1
(en)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Methods and compositions for enhancing gene editing
|
|
WO2018127585A1
(en)
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
EP3346001A1
(en)
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
US11975029B2
(en)
|
2017-02-28 |
2024-05-07 |
Vor Biopharma Inc. |
Compositions and methods for inhibition of lineage specific proteins
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
CN110832075A
(zh)
|
2017-03-22 |
2020-02-21 |
诺华股份有限公司 |
用于免疫肿瘤学的组合物和方法
|
|
CN111031790A
(zh)
|
2017-04-20 |
2020-04-17 |
E开创生物技术股份有限公司 |
产生基因修改的动物的方法
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP4410317A3
(en)
|
2017-04-28 |
2024-10-30 |
Acuitas Therapeutics Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
JP2020518245A
(ja)
|
2017-05-03 |
2020-06-25 |
サンガモ セラピューティクス， インコーポレイテッド |
嚢胞性線維症膜貫通コンダクタンス制御因子（ｃｆｔｒ）遺伝子の改変のための方法および組成物
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
EP3645721A1
(en)
|
2017-06-30 |
2020-05-06 |
Novartis AG |
Methods for the treatment of disease with gene editing systems
|
|
CA3068465A1
(en)
|
2017-06-30 |
2019-01-03 |
Precision Biosciences, Inc. |
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
|
SG11202002520UA
(en)
|
2017-09-19 |
2020-04-29 |
Univ British Columbia |
Anti-hla-a2 antibodies and methods of using the same
|
|
KR20200055037A
(ko)
|
2017-09-19 |
2020-05-20 |
메사추세츠 인스티튜트 오브 테크놀로지 |
키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
|
|
JP7317023B2
(ja)
|
2017-09-20 |
2023-07-28 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
新規抗ｈｌａ－ａ２抗体、およびその使用
|
|
WO2019089798A1
(en)
|
2017-10-31 |
2019-05-09 |
Novartis Ag |
Anti-car compositions and methods
|
|
JP2021502085A
(ja)
|
2017-11-09 |
2021-01-28 |
サンガモ セラピューティクス， インコーポレイテッド |
サイトカイン誘導性ｓｈ２含有タンパク質（ｃｉｓｈ）遺伝子の遺伝子改変
|
|
JP2021502816A
(ja)
|
2017-11-15 |
2021-02-04 |
アディセット バイオ， インコーポレイテッド |
δ３γδＴ細胞集団の選択的増殖方法及びその組成物
|
|
CN111601882A
(zh)
|
2017-11-22 |
2020-08-28 |
拉霍拉敏感及免疫学研究所 |
工程化的免疫细胞的应用和生产
|
|
JP2021507561A
(ja)
|
2017-12-14 |
2021-02-22 |
フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． |
音響トランスデューサドライバ及びコントローラ
|
|
US20190201548A1
(en)
|
2017-12-29 |
2019-07-04 |
Rubius Therapeutics, Inc. |
Gene editing and targeted transcriptional modulation for engineering erythroid cells
|
|
AU2019216269B2
(en)
|
2018-01-30 |
2025-05-01 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen
|
|
CA3089587A1
(en)
|
2018-02-08 |
2019-08-15 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
|
US20210015869A1
(en)
|
2018-04-05 |
2021-01-21 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
IL277883B2
(en)
|
2018-04-12 |
2023-12-01 |
Prec Biosciences Inc |
Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
|
|
MX2020010808A
(es)
|
2018-04-13 |
2021-03-02 |
Sangamo Therapeutics France |
Receptor de antigeno quimerico especifico para el receptor de interleucina-23.
|
|
US11421007B2
(en)
|
2018-04-18 |
2022-08-23 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (Htt)
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
US20210123075A1
(en)
|
2018-06-08 |
2021-04-29 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
MY208825A
(en)
|
2018-06-13 |
2025-05-30 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
|
AU2019318135A1
(en)
|
2018-08-10 |
2021-03-04 |
Sangamo Therapeutics France |
New car constructs comprising TNFR2 domains
|
|
CN112867792A
(zh)
|
2018-08-23 |
2021-05-28 |
桑格摩生物治疗股份有限公司 |
工程化靶特异性碱基编辑器
|
|
CN113423725A
(zh)
|
2018-08-28 |
2021-09-21 |
Vor生物制药股份有限公司 |
遗传工程化造血干细胞及其用途
|
|
KR20210060533A
(ko)
|
2018-09-18 |
2021-05-26 |
상가모 테라퓨틱스, 인코포레이티드 |
프로그램화된 세포 사멸 1 (pd1) 특이적 뉴클레아제
|
|
IL322436A
(en)
|
2018-09-21 |
2025-09-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
KR20210068478A
(ko)
|
2018-09-28 |
2021-06-09 |
메사추세츠 인스티튜트 오브 테크놀로지 |
콜라겐-국재화된 면역조정성 분자 및 그의 방법
|
|
US11453639B2
(en)
|
2019-01-11 |
2022-09-27 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
JP2022519949A
(ja)
|
2019-04-02 |
2022-03-25 |
サンガモ セラピューティクス， インコーポレイテッド |
ベータ－サラセミアの治療のための方法
|
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
EP3962519A1
(en)
|
2019-05-01 |
2022-03-09 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
KR20220016475A
(ko)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
WO2021028359A1
(en)
|
2019-08-09 |
2021-02-18 |
Sangamo Therapeutics France |
Controlled expression of chimeric antigen receptors in t cells
|
|
EP3808766A1
(en)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
|
AR120538A1
(es)
*
|
2019-11-25 |
2022-02-23 |
Univ Kyoto |
Banco de células maestras de células t
|
|
CA3168986A1
(en)
|
2020-02-26 |
2021-09-02 |
Sorrento Therapeutics, Inc. |
Activatable antigen binding proteins with universal masking moieties
|
|
KR20240096884A
(ko)
|
2020-03-10 |
2024-06-26 |
매사추세츠 인스티튜트 오브 테크놀로지 |
조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
|
|
EP4118112A1
(en)
|
2020-03-10 |
2023-01-18 |
Massachusetts Institute of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
|
IL296546A
(en)
|
2020-03-20 |
2022-11-01 |
Inst Nat Sante Rech Med |
Chimeric antigen receptor specific for human cd45rc and uses thereof
|
|
WO2021202832A1
(en)
*
|
2020-04-03 |
2021-10-07 |
Progenitor Life Sciences |
Targeting tapasin and tap complex to improve cellular immune-compatibility
|
|
US20230167191A1
(en)
|
2020-04-24 |
2023-06-01 |
Sorrento Therapeutics, Inc. |
Memory Dimeric Antigen Receptors (mDARs)
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
WO2021263008A1
(en)
|
2020-06-26 |
2021-12-30 |
The Regents Of The University Of California |
Selective addition of reagents to droplets
|
|
FI4182297T3
(fi)
|
2020-07-16 |
2025-12-05 |
Acuitas Therapeutics Inc |
Kationisia lipidejä käytettäväksi lipidinanohiukkasissa
|
|
US20230398148A1
(en)
|
2020-11-04 |
2023-12-14 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
CN116635062A
(zh)
|
2020-11-13 |
2023-08-22 |
诺华股份有限公司 |
使用表达嵌合抗原受体（car）的细胞的组合疗法
|
|
CN118019546A
(zh)
|
2021-03-23 |
2024-05-10 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途
|
|
CA3218475A1
(en)
|
2021-05-21 |
2022-11-24 |
Shipra DAS |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
|
EP4347810A4
(en)
*
|
2021-05-24 |
2025-06-04 |
Sangamo Therapeutics, Inc. |
ZINC FINGER NUCLEASES TARGETING CIITA
|
|
US12305184B2
(en)
|
2021-09-03 |
2025-05-20 |
North Carolina State University |
Compositions and methods for conferring resistance to geminivirus
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
EP4436982A1
(en)
|
2021-11-24 |
2024-10-02 |
Novartis AG |
Modulators of adeno-associated virus transduction and uses thereof
|
|
US12129223B2
(en)
|
2021-12-16 |
2024-10-29 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
EP4544058A1
(en)
*
|
2022-06-23 |
2025-04-30 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of ciita expression
|
|
US20250281613A1
(en)
|
2022-06-30 |
2025-09-11 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
|
WO2024086591A2
(en)
*
|
2022-10-17 |
2024-04-25 |
The Regents Of The University Of California |
Stem cell based delivery of tumor-specific retroviral vectors
|
|
WO2024094775A1
(en)
|
2022-11-03 |
2024-05-10 |
Cellectis S.A. |
Enhancing efficacy and safety of t-cell-mediated immunotherapy
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
EP4658675A1
(en)
|
2023-02-03 |
2025-12-10 |
C3S2 GmbH |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2025101877A1
(en)
*
|
2023-11-08 |
2025-05-15 |
The Children's Hospital Of Philadelphia |
Platform for increasing hla class i antigen presentation utilizing engineered chaperone fusion proteins
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|
|
WO2025235851A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|